Picture Berlin Partner Life Sciences Report 2019/2020 Brandenburg 650x80px
Document › Details

Mimetas B.V.. (1/13/14). "Press Release: Mimetas and Galapagos to Develop Human Disease Models On-a-Chip". Leiden.

Organisations Organisation Mimetas B.V.
  Organisation 2 Galapagos N.V. (Euronext + Nasdaq: GLPG)
  Group Galapagos (Group)
Products Product OrganoPlate™ 3D-culturing technology
  Product 2 cell microarray technology
Index term Index term Galapagos–Mimetas: organ-on-a-chip technology, 201401– collab €na developm disease model on-a-chip using OrganoPlate platform
Persons Person Janssen, Richard (Galapagos 201401 Senior Director of Target Discovery)
  Person 2 Joore, Jos (Mimetas 201410 CBO + Co-Founder)

MIMETAS and Galapagos (Euronext: GLPG) have entered into a research collaboration on the development of organ-on-a-chip-based human disease models for new medicine development.

The companies will collaborate to develop miniaturized 3D cell culture models that mimic specific aspects of human diseases. These models will be applied to the identification and improvement of novel compounds. Dr. Richard Janssen, Senior Director of Target Discovery at Galapagos, states: "The MIMETAS platform is the first to combine organ-on-a-chip technology with our high throughput screening of primary human cells. As we see it, OrganoPlates™ make 3D culture as straightforward as traditional cell culture."

Dr. Jos Joore, MIMETAS' CBO underscores this notion: "This agreement is a crucial step forward for MIMETAS and for the organ-on-a-chip field in general. Galapagos sets an example as one of the first drug discovery companies worldwide to implement innovative organ-on-a-chip technologies. This collaboration helps us to further validate our technology, by enabling development of unique novel compounds with unique human disease models."

Financial and technological details of the agreement have not been disclosed.


MIMETAS develops organ-on-a-chip technology for testing of new medicines. Its unique microfluidic technology enables testing of new medicines in high-throughput on miniaturized organ models. These models have better predictivity compared to laboratory animals and conventional cell culture models. The MIMETAS OrganoPlate™ platform allows 3D cell culture under continuous perfusion and for membrane-free co-culture, boundary and gradient formation. MIMETAS develops and validates customized disease, toxicology and transport models and ultimately will make its technology available for personalized therapy selection.

About Galapagos

Galapagos (Euronext: GLPG; OTC: GLPYY) is specialized in novel modes-of-action, with a large pipeline comprising of six Phase 2 studies (three led by GSK), one Phase 1 study, five pre-clinical, and 20 discovery small-molecule and antibody programs in cystic fibrosis, inflammation, antibiotics, metabolic disease, and other indications.

The Galapagos Group, including fee-for-service companies BioFocus, Argenta and Fidelta , has around 800 employees and operates facilities in five countries, with global headquarters in Mechelen, Belgium.

Contact Galapagos NV
Richard Janssen, Sr Director Target Discovery
+31 71 7506 700

Jos Joore, Chief Business Officer
+31 651 696 884

Record changed: 2016-01-10


Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Mimetas B.V.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81

» top